TAYLOR MORRISON HOME CORP (TMHC) Fundamental Analysis & Valuation

NYSE:TMHC • US87724P1066

Current stock price

63.24 USD
-1.09 (-1.69%)
At close:
63.24 USD
0 (0%)
After Hours:

This TMHC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. TMHC Profitability Analysis

1.1 Basic Checks

  • In the past year TMHC was profitable.
  • In the past year TMHC had a positive cash flow from operations.
  • In the past 5 years TMHC has always been profitable.
  • In the past 5 years TMHC always reported a positive cash flow from operatings.
TMHC Yearly Net Income VS EBIT VS OCF VS FCFTMHC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B

1.2 Ratios

  • TMHC's Return On Assets of 6.83% is fine compared to the rest of the industry. TMHC outperforms 75.00% of its industry peers.
  • TMHC's Return On Equity of 10.70% is fine compared to the rest of the industry. TMHC outperforms 65.00% of its industry peers.
  • With a decent Return On Invested Capital value of 8.54%, TMHC is doing good in the industry, outperforming 70.00% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for TMHC is in line with the industry average of 8.92%.
Industry RankSector Rank
ROA 6.83%
ROE 10.7%
ROIC 8.54%
ROA(3y)8.77%
ROA(5y)9.27%
ROE(3y)13.99%
ROE(5y)16.32%
ROIC(3y)10.7%
ROIC(5y)11.15%
TMHC Yearly ROA, ROE, ROICTMHC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20

1.3 Margins

  • With a decent Profit Margin value of 8.77%, TMHC is doing good in the industry, outperforming 80.00% of the companies in the same industry.
  • TMHC's Profit Margin has improved in the last couple of years.
  • TMHC has a better Operating Margin (12.86%) than 81.67% of its industry peers.
  • TMHC's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 22.59%, TMHC is doing worse than 63.33% of the companies in the same industry.
  • In the last couple of years the Gross Margin of TMHC has grown nicely.
Industry RankSector Rank
OM 12.86%
PM (TTM) 8.77%
GM 22.59%
OM growth 3Y-6.43%
OM growth 5Y13.93%
PM growth 3Y-9.03%
PM growth 5Y19.4%
GM growth 3Y-2.77%
GM growth 5Y6.54%
TMHC Yearly Profit, Operating, Gross MarginsTMHC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. TMHC Health Analysis

2.1 Basic Checks

  • TMHC has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for TMHC has been reduced compared to 1 year ago.
  • TMHC has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, TMHC has a worse debt to assets ratio.
TMHC Yearly Shares OutstandingTMHC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
TMHC Yearly Total Debt VS Total AssetsTMHC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

2.2 Solvency

  • An Altman-Z score of 3.64 indicates that TMHC is not in any danger for bankruptcy at the moment.
  • TMHC has a Altman-Z score of 3.64. This is comparable to the rest of the industry: TMHC outperforms 58.33% of its industry peers.
  • The Debt to FCF ratio of TMHC is 3.40, which is a good value as it means it would take TMHC, 3.40 years of fcf income to pay off all of its debts.
  • With a Debt to FCF ratio value of 3.40, TMHC perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
  • A Debt/Equity ratio of 0.38 indicates that TMHC is not too dependend on debt financing.
  • TMHC has a Debt to Equity ratio (0.38) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF 3.4
Altman-Z 3.64
ROIC/WACC0.91
WACC9.35%
TMHC Yearly LT Debt VS Equity VS FCFTMHC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.3 Liquidity

  • A Current Ratio of 7.00 indicates that TMHC has no problem at all paying its short term obligations.
  • TMHC's Current ratio of 7.00 is fine compared to the rest of the industry. TMHC outperforms 80.00% of its industry peers.
  • TMHC has a Quick Ratio of 7.00. This is a bad value and indicates that TMHC is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.90, TMHC perfoms like the industry average, outperforming 41.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7
Quick Ratio 0.9
TMHC Yearly Current Assets VS Current LiabilitesTMHC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. TMHC Growth Analysis

3.1 Past

  • TMHC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.81%.
  • Measured over the past years, TMHC shows a very strong growth in Earnings Per Share. The EPS has been growing by 23.33% on average per year.
  • The Revenue has decreased by -8.99% in the past year.
  • TMHC shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.79% yearly.
EPS 1Y (TTM)-21.81%
EPS 3Y-5.31%
EPS 5Y23.33%
EPS Q2Q%-45.89%
Revenue 1Y (TTM)-8.99%
Revenue growth 3Y-0.42%
Revenue growth 5Y5.79%
Sales Q2Q%-24.21%

3.2 Future

  • TMHC is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -7.38% yearly.
  • Based on estimates for the next years, TMHC will show a decrease in Revenue. The Revenue will decrease by -4.12% on average per year.
EPS Next Y-31.59%
EPS Next 2Y-7.38%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-15.63%
Revenue Next 2Y-4.12%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TMHC Yearly Revenue VS EstimatesTMHC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2B 4B 6B 8B
TMHC Yearly EPS VS EstimatesTMHC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

7

4. TMHC Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 9.29, the valuation of TMHC can be described as reasonable.
  • 86.67% of the companies in the same industry are more expensive than TMHC, based on the Price/Earnings ratio.
  • TMHC is valuated cheaply when we compare the Price/Earnings ratio to 27.42, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 9.50, the valuation of TMHC can be described as very reasonable.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of TMHC indicates a rather cheap valuation: TMHC is cheaper than 81.67% of the companies listed in the same industry.
  • TMHC is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.29, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 9.29
Fwd PE 9.5
TMHC Price Earnings VS Forward Price EarningsTMHC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • TMHC's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. TMHC is cheaper than 68.33% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, TMHC is valued cheaply inside the industry as 81.67% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 8.71
EV/EBITDA 7.52
TMHC Per share dataTMHC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80

4.3 Compensation for Growth

  • The decent profitability rating of TMHC may justify a higher PE ratio.
  • A cheap valuation may be justified as TMHC's earnings are expected to decrease with -7.38% in the coming years.
PEG (NY)N/A
PEG (5Y)0.4
EPS Next 2Y-7.38%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TMHC Dividend Analysis

5.1 Amount

  • TMHC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TMHC Fundamentals: All Metrics, Ratios and Statistics

TAYLOR MORRISON HOME CORP

NYSE:TMHC (4/24/2026, 8:11:17 PM)

After market: 63.24 0 (0%)

63.24

-1.09 (-1.69%)

Chartmill FA Rating
GICS IndustryGroupConsumer Durables & Apparel
GICS IndustryHousehold Durables
Earnings (Last)04-22
Earnings (Next)07-21
Inst Owners101.83%
Inst Owner Change1.69%
Ins Owners0.59%
Ins Owner Change13.67%
Market Cap5.99B
Revenue(TTM)7.61B
Net Income(TTM)667.66M
Analysts78.82
Price Target74.06 (17.11%)
Short Float %5.46%
Short Ratio4.21
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)13.44%
Min EPS beat(2)-1.84%
Max EPS beat(2)28.73%
EPS beat(4)2
Avg EPS beat(4)6.26%
Min EPS beat(4)-2.85%
Max EPS beat(4)28.73%
EPS beat(8)5
Avg EPS beat(8)5.23%
EPS beat(12)7
Avg EPS beat(12)5.09%
EPS beat(16)10
Avg EPS beat(16)7.06%
Revenue beat(2)1
Avg Revenue beat(2)0.54%
Min Revenue beat(2)-0.24%
Max Revenue beat(2)1.32%
Revenue beat(4)2
Avg Revenue beat(4)0.82%
Min Revenue beat(4)-2.35%
Max Revenue beat(4)4.54%
Revenue beat(8)6
Avg Revenue beat(8)1.31%
Revenue beat(12)9
Avg Revenue beat(12)2.67%
Revenue beat(16)12
Avg Revenue beat(16)2.24%
PT rev (1m)-4.22%
PT rev (3m)-3.83%
EPS NQ rev (1m)-2.07%
EPS NQ rev (3m)-21%
EPS NY rev (1m)0.47%
EPS NY rev (3m)-19.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.99%
Revenue NY rev (1m)-0.09%
Revenue NY rev (3m)-5.55%
Valuation
Industry RankSector Rank
PE 9.29
Fwd PE 9.5
P/S 0.79
P/FCF 8.71
P/OCF 8.21
P/B 0.96
P/tB 1.07
EV/EBITDA 7.52
EPS(TTM)6.81
EY10.77%
EPS(NY)6.66
Fwd EY10.53%
FCF(TTM)7.26
FCFY11.48%
OCF(TTM)7.7
OCFY12.18%
SpS80.35
BVpS65.86
TBVpS58.86
PEG (NY)N/A
PEG (5Y)0.4
Graham Number100.458 (58.85%)
Profitability
Industry RankSector Rank
ROA 6.83%
ROE 10.7%
ROCE 11.19%
ROIC 8.54%
ROICexc 9.23%
ROICexgc 10.05%
OM 12.86%
PM (TTM) 8.77%
GM 22.59%
FCFM 9.04%
ROA(3y)8.77%
ROA(5y)9.27%
ROE(3y)13.99%
ROE(5y)16.32%
ROIC(3y)10.7%
ROIC(5y)11.15%
ROICexc(3y)11.72%
ROICexc(5y)12.31%
ROICexgc(3y)13.58%
ROICexgc(5y)14.24%
ROCE(3y)14.02%
ROCE(5y)14.61%
ROICexgc growth 3Y-12.31%
ROICexgc growth 5Y15.36%
ROICexc growth 3Y-12.76%
ROICexc growth 5Y14.64%
OM growth 3Y-6.43%
OM growth 5Y13.93%
PM growth 3Y-9.03%
PM growth 5Y19.4%
GM growth 3Y-2.77%
GM growth 5Y6.54%
F-Score5
Asset Turnover0.78
Health
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF 3.4
Debt/EBITDA 2.29
Cap/Depr 99.82%
Cap/Sales 0.55%
Interest Coverage 250
Cash Conversion 71.47%
Profit Quality 103.03%
Current Ratio 7
Quick Ratio 0.9
Altman-Z 3.64
F-Score5
WACC9.35%
ROIC/WACC0.91
Cap/Depr(3y)96.24%
Cap/Depr(5y)86.45%
Cap/Sales(3y)0.46%
Cap/Sales(5y)0.41%
Profit Quality(3y)73.15%
Profit Quality(5y)75.08%
High Growth Momentum
Growth
EPS 1Y (TTM)-21.81%
EPS 3Y-5.31%
EPS 5Y23.33%
EPS Q2Q%-45.89%
EPS Next Y-31.59%
EPS Next 2Y-7.38%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-8.99%
Revenue growth 3Y-0.42%
Revenue growth 5Y5.79%
Sales Q2Q%-24.21%
Revenue Next Year-15.63%
Revenue Next 2Y-4.12%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.99%
EBIT growth 3Y-6.83%
EBIT growth 5Y20.52%
EBIT Next Year-28.23%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y129.83%
FCF growth 3Y-10.32%
FCF growth 5Y-6.47%
OCF growth 1Y122.44%
OCF growth 3Y-9.64%
OCF growth 5Y-6.16%

TAYLOR MORRISON HOME CORP / TMHC Fundamental Analysis FAQ

What is the ChartMill fundamental rating of TAYLOR MORRISON HOME CORP (TMHC) stock?

ChartMill assigns a fundamental rating of 5 / 10 to TMHC.


What is the valuation status for TMHC stock?

ChartMill assigns a valuation rating of 7 / 10 to TAYLOR MORRISON HOME CORP (TMHC). This can be considered as Undervalued.


Can you provide the profitability details for TAYLOR MORRISON HOME CORP?

TAYLOR MORRISON HOME CORP (TMHC) has a profitability rating of 7 / 10.


Can you provide the financial health for TMHC stock?

The financial health rating of TAYLOR MORRISON HOME CORP (TMHC) is 5 / 10.